Key result
Modified coronary stent architecture shows no benefit over first-generation design for 12-month TLR.
Why the study?
The impact of minor modifications in coronary stent architecture on clinical outcomes was uncertain.
Observational (n=643)
Yes
Answers are grounded in this paper and cite their sources.
No impact on 12-month TLR with modified stents; leaves open effects on other endpoints or durability.
INTRODUCTION: The objective of this study was to compare the accumulated clinical outcomes of two Malaysian all-comers populations, each treated with different polymer-free sirolimus-eluting stents (PF-SES) of similar stent design. METHODS: The Malaysian subpopulation of two all-comers observational studies based on the same protocol (ClinicalTrials.gov Identifiers: NCT02629575 and NCT02905214) were combined and compared to a Malaysian-only cohort which was treated with a later-generation PF-SES. The PF-SES's used differed only in their bare-metal backbone architecture, with otherwise identical sirolimus coating. The primary endpoint was the accumulated target lesion revascularization (TLR) rate at 12 months. The rates of major adverse cardiac events (MACE), stent thrombosis (ST) and myocardial infarction (MI) were part of the secondary endpoints. RESULTS: A total of 643 patients were treated with either the first-generation PF-SES (413 patients) or second-generation PF-SES (230 patients). Patient demographics were similar in terms of age (p = 0.744), male gender (0.987), diabetes mellitus (p = 0.293), hypertension (p = 0.905) and acute coronary syndrome (ACS, 44.8% vs. 46.1%, p = 0.752) between groups. There were no differences between treatment groups in terms of lesion length (20.8 ± 7.3 mm vs. 22.9 ± 7.9, p = 0.111) or vessel diameter (2.87 ± 0.39 vs. 2.93 ± 0.40, p = 0.052) despite numerically smaller diameters in the first-generation PF-SES group. The second-generation PF-SES tended to have more complex lesions as characterized by calcification (10.3% vs. 16.2%, p = 0.022), severe tortuosity (3.5% vs. 6.9%, p = 0.041) and B2/C lesions (49.2% vs. 62.8%, p < 0.001). The accumulated TLR rates did not differ significantly between the first- and second-generation PF-SES (0.8% vs. 0.9%, p = 0.891). The accumulated MACE rates were not significantly different (p = 0.561), at 1.5% (6/413) and 2.2% (5/230), respectively. CONCLUSIONS: Modifications in coronary stent architecture which enhance the radial strength and radiopacity without gross changes in strut thickness and design do not seem to impact clinical outcomes. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT02629575 and NCT02905214.
No takes yet. Share an insight, caveat, or question.
Nuruddin et al. (2020) conducted an observational in Coronary artery disease requiring percutaneous coronary intervention (n=643). Second-generation polymer-free sirolimus-eluting stent (Coroflex ISAR NEO) vs. First-generation polymer-free sirolimus-eluting stent (Coroflex ISAR) was evaluated on Accumulated target lesion revascularization (TLR) rate at 12 months (p=0.891). Modifications in coronary stent architecture enhancing radial strength and radiopacity did not impact the 12-month target lesion revascularization rate compared to the first-generation stent.
Synapse has enriched 10 related papers. Consider them for comparative context: